This market study shows that drug delivery technologies can help drug makers overcome some of their big challenges. The drug industry continues to see the commercial demise of major branded drugs that reach their patent expiration date. Billions of dollars in revenues are lost to generic drug makers each year. The technology can be used as part of a 'line extension' strategy to extend the commercial life of their profitable products. Drug delivery can help 'rescue' drug projects with technical challenges by using a customized delivery system. ---------------------------------------------- And also this Over the last twenty-five years, more than thirty-five transdermal patch products have been introduced to the market; however, because of physical limitations such as molecular size, these passive diffusion products encompass a narrow range of applications. Currently, the market for transdermal drug products is largely restricted to pain management, hormone replacement therapy, and cardiovascular therapy, with sales being derived from just about twelve drugs. The market for transdermals is likely to expand dramatically when macromolecules such as proteins, peptides and vaccines, can be delivered through the skin. There are a number of second generation patches under development which employ active delivery, in which the stratum corneum is breached to enhance the permeability of the skin. This includes the use of electrical, mechanical, electronic and ultrasound forces to promote drug absorption. The market should be receptive to these newer technologies, as the transdermal dosage form has been embraced by both physicians and patients because it is user-friendly, convenient and painless while offering multi-day dosing and generally improved compliance. The worldwide sales for transdermal products were nearly $13 billion in 2005 and are projected to grow at double digit rates through 2010. When compared with the total worldwide prescription drug sales of $550 billion, transdermal products account for less than 2.5 percent of the market. ------------------------------- So these are massive figures. Basically OBJ has proved with a lamb study that the patch is as good as a needle so we may well have the only patch that can tap into the $550,000,000,000.00 PA market that transdermal patches currently cannot access.
3M has already lost close to $1,000,000,000.00 in revenue due to patches coming off patent.So apart from OBJ helping it make up that ground it has the potential (if the lamb study can be replicated in humans) to help 3M attack the wider market.
This is massive dollars if it comes off. The worldwide market for transdermal patches is stated to rise to $30,000,000,000.00 pa by end of 2010. 3M control 80% of US patch market so OBJ patch gives it opportunity to attack worldwide market in transdermal even if not total drug delievery market.
If the patch works to 3M's satisfaction they WILL come on board. Add to this the cosmetic and vetinary market and we are looking at least a trillion dollars in potential markets. Please keep selling as top up time for me is almost here.
OBJ Price at posting:
2.5¢ Sentiment: LT Buy Disclosure: Held
(20min delay)